Mark W. Geraci, M.D.
Head, Division of Pulmonary Sciences
and Critical Care Medicine
Professor of Medicine
Director, Translational Medicine Program
Co-Director, Colorado Clinical
and Translational Sciences Institute’
University of Colorado Denver
Anschutz Medical Campus
Division of Pulmonary Sciences and Critical Care Medicine
MS C272, Research 2, Room 9019
12700 E 19th Avenue
Aurora, CO 80045
303.724.6037 (Assistant – Chris Weatherford)
1979-1983 University of Colorado B.A.Molecular, Cellular, Boulder, Colorado Developmental Biology and Psychology
1983-1987 Johns Hopkins University M.D. School of Medicine
1987-1990 Massachusetts General Hospital Internal Medicine Harvard Medical SchoolInternship and ResidencyBoston, Massachusetts
1990-1994 University of Colorado Fellowship Health Sciences Center Pulmonary Sciences and Critical Care Medicine Denver, Colorado
Honors and Service
1983 Phi Beta Kappa, Academic Honor Society, Graduate with Distinction, University of Colorado
1986 Lange Publications Medical Excellence Award, for highest academic performance Johns Hopkins SOM
1987 Alpha Omega Alpha, Medical Honor Society, Johns Hopkins University School of Medicine
1994-1999 NHLBI K08 Clinical Investigator Development Award
2000-Pres Ad Hoc Member, NIH Peer Review Study Sections (23 total), SBIR/STTR, NRSA, NINDS, NIEHS, NIAMS
2005-2009 Regular Member, NIH SMEP Study Section
2005-Pres Editorial Board, Experimental Biology and Medicine
2006-Pres Associate Editor, Clinical Translational Science
2009-Pres Editorial Board, American Journal of Respiratory and Critical Care Medicine (AJRCCM)
2009-Pres Editorial Board, American Journal of Respiratory Cell and Molecular Biology (AJRCMB)
1987-1990 Medical Internship / Residency, Massachusetts General Hospital, Boston, MA
1990-1994 Fellow→Instructor, University of Colorado Denver, Denver, CO
1994-2005 Assistant Professor → Professor, Department of Medicine, UCDHSC, Denver, CO.
2005-Pres Professor with Tenure, Department of Medicine, UCD, Denver, CO.
1999-Pres Director, Genomics Core Facility, UCD, Denver, CO.
2004-Pres Director, Translational Medicine Program, UCD, Denver, CO.
2004-Pres Head, Division of Pulmonary Sciences and Critical Care Medicine, UCD, Denver, CO.
The Role of Eicosanoids in Pulmonary Hypertension and Lung Cancer:
My laboratory has had a long-standing interest in the role of selected eicosanoids and their role in the development of both pulmonary hypertension and lung cancer. We have accomplished the following:
• Cloning of the full-length rat prostacyclin synthase (PGIS) cDNA.
• Demonstration of decreased PGIS in primary pulmonary hypertension.
• Development of transgenic animals with pulmonary specific overexpression of PGIS
• Demonstration that these animals are completely protected form the development of pulmonary hypertension.
• Induction of pulmonary hypertension with targeted disruption of prostacyclin receptor.
• Prevention of tumorigenesis with PGIS overexpression.
• Lung cancer chemoprevention trial using Iloprost, a long-acting oral analogue of prostacyclin. SPORE in Lung Cancer Administrative Supplement, National Institutes of Health, National Cancer Institute. “A Randomized Phase II Chemoprevention Study of Iloprost versus Placebo in Patients at High Risk for Lung Cancer”. Grant # 3 P50 CA 58187-08S2. SPORE PI – Paul A. Bunn, Jr. MD. Supplement PI – Robert L. Keith MD. 11/01-12/08, $429,778 (Mentor on Project for Keith).